You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Corporate Strategic Plan 2026 (CSP2026) defines our direction, priorities, and ambitions for the next five years, guiding how we create VALUE and drive sustainable growth.
Corporate Strategic Plan 2026, or CSP2026, is our five-year plan to drive sustainable growth, create and deliver greater VALUE faster for patients, and address evolving unmet medical needs. It is also an exciting opportunity for us to shape our growth and transformation together.
CSP2026 embodies our shared ambition and showcases Astellas at its very best – anchored in Integrity, Innovation, and Impact. I am confident in our path forward as we shape a better future together and bring to life our VISION: On the forefront of healthcare change to turn innovative science into VALUE for patients.
Representative Director, President and Chief Executive Officer (CEO)
Watch the on-demand replay of the CSP2026 online meeting presented by Naoki Okamura, President and CEO, and access the presentation material via the link below.
Our VISION:
CSP2026 Overview
Our ambition is to achieve pipeline-led, record-high revenues by mid-2030s.
To create and deliver greater VALUE faster for patients
VALUE Delivery
VALUE Creation
Focus Area Approach | Pursue innovation to create and deliver VALUE
Driving forward the most promising assets to treat diseases where the need is greatest
and impact could be life-changing
R&D Investment for Acceleration (FY2026-2030)
(i) ADC: (immunostimulatory) Antibody-drug conjugate, BD: Business Development, G/GEJ: Gastric/gastroesophageal junction, mRNA: messenger RNA, NSCLC: Non-small cell lung cancer, PDAC: Pancreatic ductal adenocarcinoma, PoC: Proof of concept, SM: Small molecule, TCE: T-cell engager, TPD: Targeted protein degrader
Create and deliver greater VALUE faster
Cash Allocation
Allocate capital with clear profitability guardrails to fund R&D investment and deliver shareholder value.
How We Deliver
Productivity Enhancement | Build on how we operate
These Values and Behaviors will guide our ways of working throughout the CSP2026 as we work to turn innovative science into VALUE for patients
Watch the on-demand replay of the CSP2026 online meeting presented by Naoki Okamura, President and CEO, and access the presentation material via the link below.
Sustainability
Alongside these CSP2026 goals, Astellas maintains our strong, organization-wide commitment to sustainability that supports long-term corporate value. Our approach to sustainability is to contribute to society through our core business first – and to create a positive cycle that improves the sustainability of both society and Astellas.
Our 9 Key Sustainability Priorities (Materiality)
We developed the Sustainability Diagram (below) with newly identified nine material topics related to sustainability. The nine material topics are organized under three pillars – Trust, Innovation, and People – and the Diagram illustrates how these inter-connected topics create a positive cycle for both society and Astellas. By addressing these material topics through our core business, Astellas aims to create and deliver VALUE for society while simultaneous advancing the realization of our VISION.
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapy in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need.
